INNOVIVA, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
INNOVIVA, INC. (INVA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 0.09% for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-28.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2017-02-28
- INNOVIVA, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2016 was 0.09%.
- INNOVIVA, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2015 was -0.23%.
- INNOVIVA, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2014 was -1.11%, a 496.43% decline from fiscal 2013.
- INNOVIVA, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2013 was 0.28%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2016-12-31 | 0.09% 10-K · filed 2017-02-28 |
| 2015-12-31 | -0.23% 10-K · filed 2017-02-28 |
| 2014-12-31 | -1.11% 10-K · filed 2017-02-28 |
| 2013-12-31 | 0.28% 10-K · filed 2016-02-24 |
| 2012-12-31 | -1.36% 10-K · filed 2015-02-27 |
| 2011-12-31 | -0.32% 10-K · filed 2014-03-03 |
| 2010-12-31 | 2.29% 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |